Mereo Biopharma Group PLCNASDAQ:MREO
- LAST PRICE1.2900
- TODAY'S CHANGE (%)-0.0200 (-1.5267%)
- Bid / Lots1.2900/ 10
- Ask / Lots1.3200/ 11
- Open / Previous Close1.3400 / 1.3100
- Day Range
- 52 Week Range
- Volume590,500
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 3912 | 1.31 |
| 09:34 ET | 2000 | 1.32 |
| 09:36 ET | 850 | 1.315 |
| 09:38 ET | 3500 | 1.3195 |
| 09:39 ET | 100 | 1.315 |
| 09:41 ET | 2173 | 1.3194 |
| 09:43 ET | 3177 | 1.3 |
| 09:45 ET | 100 | 1.3 |
| 09:48 ET | 7138 | 1.3004 |
| 09:50 ET | 8607 | 1.295 |
| 09:54 ET | 16479 | 1.2931 |
| 09:56 ET | 4450 | 1.295 |
| 09:57 ET | 7509 | 1.2901 |
| 09:59 ET | 26261 | 1.2872 |
| 10:01 ET | 1399 | 1.28 |
| 10:06 ET | 5800 | 1.2895 |
| 10:08 ET | 3000 | 1.2899 |
| 10:10 ET | 3700 | 1.2899 |
| 10:12 ET | 8150 | 1.29 |
| 10:14 ET | 2600 | 1.29 |
| 10:15 ET | 100 | 1.29 |
| 10:17 ET | 8449 | 1.29 |
| 10:19 ET | 7739 | 1.28 |
| 10:21 ET | 43954 | 1.26 |
| 10:24 ET | 2900 | 1.2799 |
| 10:26 ET | 15568 | 1.28 |
| 10:28 ET | 1050 | 1.28 |
| 10:30 ET | 4918 | 1.27 |
| 10:32 ET | 1540 | 1.28 |
| 10:33 ET | 200 | 1.285 |
| 10:35 ET | 177 | 1.285 |
| 10:39 ET | 1000 | 1.285 |
| 10:42 ET | 6615 | 1.29 |
| 10:44 ET | 400 | 1.29 |
| 10:46 ET | 3200 | 1.2905 |
| 10:48 ET | 100 | 1.29 |
| 10:51 ET | 100 | 1.295 |
| 10:53 ET | 5500 | 1.3 |
| 10:55 ET | 108 | 1.295 |
| 10:57 ET | 100 | 1.295 |
| 11:08 ET | 2698 | 1.295 |
| 11:11 ET | 1000 | 1.295 |
| 11:20 ET | 900 | 1.285 |
| 11:22 ET | 100 | 1.2993 |
| 11:24 ET | 120 | 1.2918 |
| 11:26 ET | 100 | 1.29 |
| 11:27 ET | 206 | 1.2918 |
| 11:29 ET | 4493 | 1.29 |
| 11:31 ET | 100 | 1.295 |
| 11:40 ET | 100 | 1.295 |
| 11:42 ET | 100 | 1.29 |
| 11:44 ET | 216 | 1.29 |
| 11:45 ET | 300 | 1.29 |
| 11:47 ET | 5589 | 1.29 |
| 11:49 ET | 100 | 1.295 |
| 11:51 ET | 100 | 1.295 |
| 11:54 ET | 1100 | 1.2901 |
| 11:56 ET | 200 | 1.295 |
| 11:58 ET | 100 | 1.295 |
| 12:02 ET | 5200 | 1.2901 |
| 12:03 ET | 100 | 1.2998 |
| 12:05 ET | 1400 | 1.3 |
| 12:07 ET | 2830 | 1.305 |
| 12:09 ET | 600 | 1.3091 |
| 12:12 ET | 400 | 1.3 |
| 12:16 ET | 100 | 1.305 |
| 12:18 ET | 400 | 1.3 |
| 12:20 ET | 100 | 1.305 |
| 12:21 ET | 100 | 1.305 |
| 12:25 ET | 100 | 1.305 |
| 12:30 ET | 13000 | 1.3 |
| 12:32 ET | 2741 | 1.3 |
| 12:34 ET | 500 | 1.2935 |
| 12:41 ET | 100 | 1.29 |
| 12:43 ET | 100 | 1.2977 |
| 12:45 ET | 13800 | 1.2907 |
| 12:48 ET | 100 | 1.2999 |
| 12:52 ET | 9860 | 1.285 |
| 12:54 ET | 400 | 1.29 |
| 12:56 ET | 2258 | 1.29 |
| 12:57 ET | 300 | 1.2999 |
| 12:59 ET | 2613 | 1.29 |
| 01:03 ET | 353 | 1.29 |
| 01:06 ET | 7427 | 1.2901 |
| 01:08 ET | 3400 | 1.2895 |
| 01:24 ET | 4989 | 1.285 |
| 01:26 ET | 2100 | 1.285 |
| 01:28 ET | 200 | 1.28 |
| 01:32 ET | 574 | 1.285 |
| 01:33 ET | 2741 | 1.29 |
| 01:35 ET | 100 | 1.295 |
| 01:37 ET | 5100 | 1.29 |
| 01:39 ET | 2682 | 1.305 |
| 01:42 ET | 1300 | 1.3 |
| 01:44 ET | 11537 | 1.3 |
| 01:46 ET | 750 | 1.2892 |
| 01:48 ET | 18520 | 1.29 |
| 01:51 ET | 12384 | 1.29 |
| 01:53 ET | 1000 | 1.29 |
| 01:55 ET | 14451 | 1.29 |
| 02:00 ET | 100 | 1.285 |
| 02:02 ET | 300 | 1.285 |
| 02:04 ET | 200 | 1.285 |
| 02:06 ET | 8828 | 1.2985 |
| 02:08 ET | 300 | 1.29 |
| 02:09 ET | 885 | 1.29 |
| 02:13 ET | 200 | 1.295 |
| 02:15 ET | 200 | 1.295 |
| 02:18 ET | 200 | 1.295 |
| 02:20 ET | 4440 | 1.295 |
| 02:22 ET | 100 | 1.295 |
| 02:31 ET | 100 | 1.295 |
| 02:33 ET | 200 | 1.295 |
| 02:40 ET | 100 | 1.295 |
| 02:42 ET | 100 | 1.295 |
| 02:47 ET | 300 | 1.295 |
| 02:49 ET | 500 | 1.295 |
| 02:54 ET | 1600 | 1.3 |
| 02:56 ET | 100 | 1.295 |
| 02:58 ET | 200 | 1.295 |
| 03:00 ET | 500 | 1.295 |
| 03:02 ET | 100 | 1.295 |
| 03:03 ET | 100 | 1.295 |
| 03:05 ET | 100 | 1.295 |
| 03:09 ET | 300 | 1.29 |
| 03:14 ET | 5450 | 1.3 |
| 03:16 ET | 200 | 1.305 |
| 03:18 ET | 767 | 1.3 |
| 03:20 ET | 954 | 1.3 |
| 03:25 ET | 140 | 1.295 |
| 03:34 ET | 9266 | 1.31 |
| 03:36 ET | 6313 | 1.31 |
| 03:38 ET | 1500 | 1.31 |
| 03:39 ET | 500 | 1.31 |
| 03:41 ET | 3336 | 1.315 |
| 03:43 ET | 7373 | 1.315 |
| 03:45 ET | 650 | 1.315 |
| 03:48 ET | 100 | 1.31 |
| 03:50 ET | 45407 | 1.295 |
| 03:52 ET | 3063 | 1.3 |
| 03:54 ET | 7660 | 1.295 |
| 03:56 ET | 3000 | 1.295 |
| 03:57 ET | 2966 | 1.295 |
| 03:59 ET | 7330 | 1.29 |
Sep 21, 2023
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference, from 7:00AM ET on Thursday Sep 21, 2023 by Dow Jones
7:00AM ET on Thursday Sep 21, 2023 by Dow Jones
Sep 8, 2023
DJ Mereo BioPharma Group Price Target Maintained With a $4.00/Share by Cantor Fitzgerald, from 10:04AM ET on Friday Sep 08, 2023 by Dow Jones
10:04AM ET on Friday Sep 08, 2023 by Dow JonesDJ Mereo BioPharma Group Price Target Maintained With a $5.00/Share by Needham, from 4:28AM ET on Friday Sep 08, 2023 by Dow Jones
4:28AM ET on Friday Sep 08, 2023 by Dow Jones
Sep 7, 2023
Press Release: Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update, from 7:30AM ET on Thursday Sep 07, 2023 by Dow Jones
7:30AM ET on Thursday Sep 07, 2023 by Dow JonesMereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update, from 7:30AM ET on Thursday Sep 07, 2023 by Dow Jones
7:30AM ET on Thursday Sep 07, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo Biopharma Group PLC | 183.7M | -0.2x | --- |
Astria Therapeutics Inc | 225.7M | -3.1x | --- |
Aeon Biopharma Inc | 221.4M | -13.6x | --- |
Immuneering Corp | 229.1M | -4.0x | --- |
Acrivon Therapeutics Inc | 218.5M | -5.0x | --- |
ATAI Life Sciences NV | 215.8M | -1.4x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Contact Information
- Headquarters
- Fourth Fl, 1 Cavendish PlaceLONDON, United Kingdom W1G 0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Peter Fellner
- Chief Executive Officer, Director
- Denise Scots-Knight
- Non-Executive Independent Deputy Chairman of the Board
- Michael Wyzga
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $183.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 140.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.92 |
EPS | $-7.11 |
Book Value | $0.60 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
